ESMO E-Learning: Modern Management of DLBCL

Learning Objectives

  • To provide an update on classification, molecular biology and outcomes of diffuse large B-cell lymphoma (DLBCL)
  • To provide an update on advances in first-line management of patients with DLBCL
  • To provide an update on management of patients with relapsed DLBCL
Title Duration Content CME Points CME Test
Modern Management of DLBCL 54 min. 56 slides 1 Take Test
pettengel-ruth
Ruth Pettengell
Read more

Diffuse large B-cell lymphoma (DLBCL) is the most common form of B-cell lymphomas. The outcome of DLBCL has improved with the addition of rituximab (R) to CHOP chemotherapy regimen. Patients who fail R-CHOP have a dismal outcome. Selectivity of targeted agents underlines the importance of molecular subtyping at relapse. There is a plethora of new agents, but the studies generally include very few patients with DLBCL. This ESMO E-Learning module gives a short summary devoted to advances in the management of patients with DLBCL.

In terms of first-line treatment, the author emphasizes that we are getting closer to understanding the distinct biology of the different subtypes of lymphomas. R-CHOP remains the standard of care, but it is likely that in the future, in certain subgroups, R-CHOP will be combined with another therapy. The author underlines that it is unlikely to make progress with one-size-fits- all chemotherapy in patients with DLBCL.

Furthermore, the author states that there is the need to better understand prognostic markers in DLBCL, in order to better target therapies and design clinical trials.

In case of relapse, subtype and histology matter. Further factors to take into consideration are comorbidities, previous therapies, responses and duration of response, patient’s functional status, and patient’s preferences. In general, relapsed DLBCL has a poor prognosis. The author reviews the treatment possibilities in relapsed and refractory settings.

Overall, this module is an excellent opportunity to keep abreast with advances in the management of DLBCL. The author provides an overview of incidence, classification revision, prognosis and prognostic scores, treatment algorithms and updates on recent advances in first-line treatment and management of relapsed/refractory disease.

Last update: 30 May 2017

The author has reported no conflicts of interest